Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.61 |
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20137011 | 0.99 | MGLL (0.60) | MGLLPTGDR2MAPTTDP1KDM4E | |
| Hydrochloric Acid SCHEMBL29561336 | 0.99 | MGLL (0.60) | MGLLPTGDR2MAPTTDP1KDM4E | |
| SCHEMBL4106882 | 0.90 | PTGDR2 (0.67) | PTGDR2MAPT | |
| SCHEMBL20570570 | 0.80 | MGLL (0.48) | MGLLPTGDR2KDM4EALDH1A1 | |
| SCHEMBL30457753 | 0.80 | MGLL (0.48) | MGLLPTGDR2KDM4EALDH1A1 | |
| SCHEMBL28322529 | 0.78 | DDR1 (0.49) | MGLL | |
| SCHEMBL28887675 | 0.78 | DDR1 (0.42) | MGLLTDP1KDM4EALDH1A1 | |
| SCHEMBL4274174 | 0.77 | HTR3E (0.60) | PTGDR2MAPTTDP1 | |
| Succinic Acid SCHEMBL31581233 | 0.76 | PTGDR2 (0.52) | PTGDR2KDM4E | |
| SCHEMBL20137042 | 0.76 | MGLL (1.00) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018093947-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134674-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | MGLL 3/4885PTGDR2 1360/4885MAPT 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.